Evidence map›Paper›PMID 40010749›Full record

ArticleBiomarkers in medicine2025

NLR as prognostic biomarker for metastatic renal cell carcinoma patients treated with cytoreductive nephrectomy.

Huanrui Liu, Senlin Li, Fan Zhang, Weiyang He, Xin Gou, Xu Zhang, Yongpeng Xie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Huanrui LiuDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Senlin LiDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Fan ZhangDepartment of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, China.
Weiyang HeDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xin GouDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xu ZhangDepartment of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, China.
Yongpeng XieDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID 0009-0007-7790-3194

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to determine the prognostic value of preoperative Neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic renal cell carcinoma (mRCC) undergoing cytoreductive nephrectomy (CN).

methodsWe retrospectively investigated the clinicopathological data of patients with mRCC from two Chinese hospitals (2008-2018). Patients were stratified and analyzed for survival prognosis using X-tile software, Kaplan-Meier curves, log-rank test, and univariate/multivariate Cox regression analyses.

resultsThe patients were divided into low NLR group (≤2.7) and high NLR group (>2.7) based on the optimal cutoff value of 2.7 obtained using the X-tile software, containing 137 and 93 patients, respectively. Kaplan - Meier analysis indicated that high NLR group had significantly inferior median progression-free survival (PFS) and overall survival (OS) than low NLR group (median PFS of 8.3 months vs. 17.9 months,

conclusionsElevated preoperative NLR demonstrates significant association with poor survival in post-CN mRCC patients and may facilitate clinical decision-making.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellCytoreduction Surgical ProceduresKidney NeoplasmsLymphocytesNephrectomyNeutrophilsAdultAgedFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisPrognosisBiomarkers, Tumorbiomarkercytoreductive nephrectomyneutrophil-to-lymphocyte ratioprognosticRenal cell carcinoma

Identifiers

PMID40010749
PMCPMC11916357

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.